Stefania Bellone

10.0k total citations
155 papers, 5.4k citations indexed

About

Stefania Bellone is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Stefania Bellone has authored 155 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 53 papers in Immunology and 36 papers in Molecular Biology. Recurrent topics in Stefania Bellone's work include HER2/EGFR in Cancer Research (41 papers), Immunotherapy and Immune Responses (35 papers) and Monoclonal and Polyclonal Antibodies Research (29 papers). Stefania Bellone is often cited by papers focused on HER2/EGFR in Cancer Research (41 papers), Immunotherapy and Immune Responses (35 papers) and Monoclonal and Polyclonal Antibodies Research (29 papers). Stefania Bellone collaborates with scholars based in United States, Italy and China. Stefania Bellone's co-authors include Alessandro D. Santin, Sërgio Pecorelli, Martin J. Cannon, Juan J. Roman, Michela Palmieri, Peter E. Schwartz, Emiliano Cocco, Thomas Rutherford, Natália Buza and Antonella Ravaggi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Stefania Bellone

149 papers receiving 5.3k citations

Peers

Countries citing papers authored by Stefania Bellone

Since Specialization

Citations

This map shows the geographic impact of Stefania Bellone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefania Bellone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefania Bellone more than expected).

Fields of papers citing papers by Stefania Bellone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefania Bellone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefania Bellone. The network helps show where Stefania Bellone may publish in the future.

Co-authorship network of co-authors of Stefania Bellone

This figure shows the co-authorship network connecting the top 25 collaborators of Stefania Bellone. A scholar is included among the top collaborators of Stefania Bellone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefania Bellone. Stefania Bellone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TET3 is a common epigenetic immunomodulator of pathogenic macrophages 2025 ·Journal of Clinical Investigation ·Beibei Liu, Yangyang Dai, Zixin Wang, Jiahui Song, Yingying Du, Haining Lv, Stefania Bellone, (unknown), Andrew Kennedy, Songying Zhang, (unknown), Yulia V. Surovtseva, Penghua Wang, Gordon Carmichael, Hugh S. Taylor, Xuchen Zhang, Da Li, Yingqun Huang	2
2	Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma 2025 ·Cancer Research Communications ·(unknown), (unknown), Stefania Bellone, Tobias M.P. Hartwich, Blair McNamara, (unknown), (unknown), (unknown), Yang Yang‐Hartwich, (unknown), Elena Ratner, Alessandro D. Santin	1
3	Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor 2025 ·International Journal of Molecular Sciences ·(unknown), Stefania Bellone, (unknown), (unknown), Tobias M.P. Hartwich, Blair McNamara, (unknown), Yang Yang‐Hartwich, Elena Ratner, (unknown), (unknown), (unknown), (unknown), Jonathan A. Pachter, (unknown), Alessandro D. Santin	0
4	Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models 2025 ·International Journal of Gynecological Cancer ·(unknown), (unknown), (unknown), Stefania Bellone, (unknown), Tobias M.P. Hartwich, (unknown), Natália Buza, Roberto Angioli, Francesco Plotti, (unknown), Alessandro D. Santin	0
5	Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas 2025 ·Cancer Research Communications ·(unknown), (unknown), Stefania Bellone, (unknown), (unknown), (unknown), Blair McNamara, Natália Buza, Tobias M.P. Hartwich, (unknown), Domenica Lorusso, Alessandro D. Santin	0
6	TET3-overexpressing macrophages promote endometriosis 2024 ·Journal of Clinical Investigation ·Haining Lv, Beibei Liu, Yangyang Dai, (unknown), Stefania Bellone, Yuping Zhou, Ramanaiah Mamillapalli, Dejian Zhao, (unknown), (unknown), Gordon Carmichael, Da Li, Hugh S. Taylor, Yingqun Huang	11
7	Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer 2024 ·Cancer Medicine ·Tobias M.P. Hartwich, (unknown), (unknown), (unknown), Stefania Bellone, (unknown), Shuvro P. Nandi, Ludmil B. Alexandrov, Yang Yang‐Hartwich, Sílvia Coma, Jonathan A. Pachter, Alessandro D. Santin	5
8	Abstract 4104: Randomized phase II trial of imiquimod with or without 9vHPV vs observation in patients with CIN 2 and 3 2024 ·Cancer Research ·Sangini S. Sheth, Ji Eun Oh, Stefania Bellone, Eric R. Siegel, Natália Buza, Akiko Iwasaki, Alessandro D. Santin	0
9	Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma 2022 ·Cancer Discovery ·Ryan D. Chow, (unknown), Stefania Bellone, Tobias M.P. Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro D. Santin	40
10	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma 2020 ·Gynecologic Oncology Reports ·(unknown), Natália Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin	6
11	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement 2018 ·Clinical Cancer Research ·Stefania Bellone, Natália Buza, Jungmin Choi, Luca Zammataro, Laurie M. Gay, Julia A. Elvin, David L. Rimm, Yuting Liu, Elena Ratner, Peter E. Schwartz, Alessandro D. Santin	35
12	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo 2017 ·Medical Oncology ·Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan D. Black, Salvatore Lopez, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Babak Litkouhi, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin	15
13	Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo 2015 ·Gynecologic Oncology ·Carlton L. Schwab, Diana P. English, Jonathan Black, Stefania Bellone, Salvatore Lopez, Emiliano Cocco, Elena Bonazzoli, Beatrice Bussi, Federica Predolini, Francesca Ferrari, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin	26
14	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo 2015 ·Molecular Cancer Therapeutics ·Salvatore Lopez, Emiliano Cocco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Diana P. English, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Corrado Terranova, Roberto Angioli, Alessandro D. Santin	26
15	Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo 2014 ·Gynecologic Oncology ·Carlton L. Schwab, Diana P. English, Dana M. Roque, Stefania Bellone, Salvatore Lopez, Emiliano Cocco, Roberta Nicoletti, Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin	27
16	HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas 2012 ·International Journal of Gynecological Pathology ·Federica Guzzo, Stefania Bellone, Natália Buza, Pei Hui, Luisa Carrara, Joyce Varughese, Emiliano Cocco, Marta Betti, Paola Todeschini, Sara Gasparrini, Peter E. Schwartz, Thomas Rutherford, Roberto Angioli, Sërgio Pecorelli, Alessandro D. Santin	33
17	High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody 2010 ·American Journal of Obstetrics and Gynecology ·C. Richter, Emiliano Cocco, Stefania Bellone, Dan‐Arin Silasi, Dominik Rüttinger, Masoud Azodi, Peter E. Schwartz, Thomas Rutherford, Sërgio Pecorelli, Alessandro D. Santin	29
18	The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer 2004 ·American Journal of Obstetrics and Gynecology ·Stefania Canè, Eliana Bignotti, Stefania Bellone, Michela Palmieri, Luis E. De Las Casas, Juan J. Roman, Sërgio Pecorelli, Martin J. Cannon, (unknown), Alessandro D. Santin	35
19	Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy 2003 ·Gynecologic Oncology ·Stefania Bellone, Michela Palmieri, Murat Gökden, (unknown), Juan J. Roman, Sërgio Pecorelli, Martin J. Cannon, Alessandro D. Santin	29
20	Overexpression of HER-2/neu in uterine serous papillary cancer. 2002 ·PubMed ·Alessandro D. Santin, Stefania Bellone, Murat Gökden, Michela Palmieri, Donna Dunn, (unknown), Juan J. Roman, Laura F. Hutchins, Sërgio Pecorelli, Timothy O’Brien, Martin J. Cannon, Groesbeck P. Parham	143

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact